21例原发性胸壁尤因肉瘤的临床分析

江丽丽, 马妍, 张田田, 黄山

  1. 苏州大学附属第一医院病理科,江苏 苏州 215000
  • 收稿日期:2023-08-02 修回日期:2023-12-20 出版日期:2024-01-30 发布日期:2024-02-05
  • 通信作者: 黄山
  • 作者简介:江丽丽(ORCID: 0009-0009-8774-8938),硕士,主管技师。

摘要/Abstract

摘要:

背景与目的:原发性胸壁尤因肉瘤(primary Ewing sarcoma of the thoracic wall,PEST)是发生在胸壁或胸腔的罕见骨外尤因肉瘤。PEST患者生存期短,预后差,复发率高。PEST发病原因未明,发展迅速,早诊断、早治疗是提高患者生存率的有效手段。本研究通过收集PEST病例,探讨其临床病理学特征、治疗方法及预后,以提高临床对该病的认识及诊疗水平。方法:回顾性分析2018—2023年苏州大学附属第一医院收治的及文献报道的共21例PEST患者的临床资料、病理学特征、治疗及随访结果,采用Kaplan-Meier法计算年龄与累积生存率的关系。结果:全组PEST患者男女比例为13:8,左右胸比例为6:15,中位年龄为20岁,平均年龄为28岁,中位肿瘤直径为8.0 cm,平均肿瘤直径为18.1 cm。65.2%患者同侧胸腹痛,47.6%患者侵犯同侧肋骨伴胸腔积液。病理学检查符合肿瘤特征,瘤细胞呈紧密成片或小叶状分布的蓝色小圆细胞,100% CD99弥漫强阳性,80%波形蛋白(vimentin)阳性。苏州大学附属第一医院收治的2例患者荧光原位杂交(fluorescence in situ hybridization,FISH)检测可见EWSR1分离信号,二代测序(next-generation sequencing,NGS)可见EWSR1-FLI1融合。2例患者术前接受新辅助化疗,10例术后接受放化疗,5例仅接受放化疗,1例仅接受手术治疗,3例无手术资料。全组患者随访时间为3~38个月,7例失访。患者的发病年龄与累积生存率呈正相关,平均生存时间为19.98个月,中位生存时间为13.00个月。结论:PEST多见于年轻男性,易发生于右胸,肿物常大于8 cm,大部分病例可通过病理形态学、免疫表型初诊,FISH或NGS行EWSR1基因检测可提供精确诊断。PEST患者预后极差,累积生存率与发病年龄呈正相关,手术、放疗及化疗为PEST的主要治疗手段。

关键词: 原发性胸壁尤因肉瘤, 临床病理学特征, 治疗, EWSR1-FLI1

Abstract:

Background and Purpose: Primary Ewing sarcoma of the thoracic wall (PEST) is a rare extraosseous Ewing sarcoma that occurs in the chest wall or thoracic cavity with a short survival, poor prognosis and a high rate of recurrence. Early diagnosis and treatment are the best way to prolong survival time since the cause of PEST is not clear. This study aimed to explore the clinicopathologic characteristics, diagnosis and treatment of PEST to improve clinical understanding of this disease. Methods: A total of 21 cases with PEST were treated at The First Affiliated Hospital of Soochow University, and reviews were published from 2018 to 2023. Clinical data, pathological features, treatment and follow-up of the patients were analyzed respectively. The survival was from the start of treatment to the death of the patient or the end of the follow-up. Cumulative survival was estimated by Kaplan-Meier method. Results: A total of 21 cases with PEST (male/female ratio, 13:8; sites of left/right chest ratio, 6:15; median age, 20 years; mean age, 28 years; median diameter of the tumor, 8.0 cm; mean diameter of the tumor, 18.1 cm) met the inclusion criteria. 65.2% of the patients presented with the pain in the ipsilateral thoracic and abdominal area. In 47.1% of cases, the ipsilateral ribs were invaded with pleural effusion. Pathological morphology microscopy showed most tumor cells were tightly packed or lobular distribution of small blue round cells. In immunohistochemistry, CD99 and vimentin were positive in 100% and 80% cases respectively while neurogenic markers were expressed to varying degrees. EWSR1 separated signal was found by fluorescence in situ hybridization (FISH), and the EWSR1-FLI1 fusion was detected by next-generation sequencing (NGS) in two cases at our hospital. Two cases received neoadjuvant chemotherapy, 10 patients received chemotherapy and radiotherapy after operation, 5 cases were treated with radiotherapy only, 1 case received surgery only, and 3 cases had no surgical data. A total of 14 cases were followed up for 3-38 month while 7 cases were lost to visit. Cumulative survival correlates with age at disease. The mean survival time was 19.98 months, and the median survival time was 13.00 months. Conclusion: Young males, right chest and the mass larger than 8 cm are more often found. Most cases can be initially diagnosed using histopathology and immunohistochemical markers. FISH or NGS of the EWSR1 gene test are a highly accurate method for diagnosis. The prognosis of PEST is extremely poor, and the cumulative survival rate is negatively correlated with the age of onset. Surgery, radiotherapy and chemotherapy are the main treatments for this disease.

Key words: Primary Ewing sarcoma of the thoracic wall, Clinicopathological features, Treatment, EWSR1-FLI1

中图分类号: 

相关文章

[1] 上海市抗癌协会癌症康复与姑息治疗专业委员会, 上海市抗癌协会肿瘤药物临床研究专业委员会, 中国老年保健协会肿瘤防治与临床研究管理专业委员会. 抗肿瘤治疗所致恶心呕吐全程管理上海专家共识(2024年版)[J]. 中国癌症杂志, 2024, 34(1): 104-134.
[2] 杨彦举, 方应涛, 高大地, 王佳舟, 赵俊, 胡伟刚. uRT-TPS和Monaco-TPS对同一直线加速器在多癌种放射剂量计算方面差异的比较[J]. 中国癌症杂志, 2024, 34(1): 82-89.
[3] 刘雪柔, 杨玉梅, 赵倩, 荣翔宇, 刘伟, 郑瑞洁, 庞金龙, 李娴, 李姗姗. 谷氨酰胺代谢相关蛋白在肿瘤转移中的作用研究进展[J]. 中国癌症杂志, 2024, 34(1): 97-103.
[4] 魏晶, 何雅琪, 薛田, 柏乾明, 水若鸿, 陆洪芬, 李小秋, 于宝华. 伴MYC、BCL2、BCL6基因重排的DLBCL/HGBL临床病理学特征分析[J]. 中国癌症杂志, 2023, 33(9): 809-817.
[5] 吴晗, 杨章孺, 冯雯, 曾琬琴, 郭金栋, 李洪选, 王常禄, 王家明, 吕长兴, 张琴, 余雯, 蔡旭伟, 傅小龙. 多原发性早期肺癌立体定向放射治疗后疗效及患者预后分析[J]. 中国癌症杂志, 2023, 33(9): 844-856.
[6] 康殷楠, 陈顺, 解有成, 郑英, 何昱静, 李初谊, 于晓辉. 抗体药物偶联物在HER2阳性晚期胃癌中的应用进展和展望[J]. 中国癌症杂志, 2023, 33(8): 790-800.
[7] 王若曦, 吉芃, 龚悦, 陈盛. HER2低表达乳腺癌新辅助化疗效果及其预后特征:一项单中心回顾性研究[J]. 中国癌症杂志, 2023, 33(7): 686-692.
[8] 郑伟涛, 李涵泺, 胡康洪. TCR-T免疫治疗肿瘤:现状、挑战及展望[J]. 中国癌症杂志, 2023, 33(7): 707-716.
[9] 黄鹤, 鞠侯雨, 杨文艺, 严明, 任国欣, 胡镜宙. PD-L2在头颈部鳞状细胞癌免疫治疗预后评估中的意义[J]. 中国癌症杂志, 2023, 33(6): 613-618.
[10] 左学良, 陈志强, 董润雨, 王智雄, 蔡娟. 联合检测LDHA和PD-L1在晚期胃癌PD-1抑制剂疗效预测及预后评估中的价值[J]. 中国癌症杂志, 2023, 33(5): 460-468.
[11] 杨闻箫, 国琳玮, 凌泓, 胡欣. 基于免疫微环境特征的曲妥珠单抗与免疫治疗联合应用预测模型[J]. 中国癌症杂志, 2023, 33(5): 484-498.
[12] 陈君瑶, 张文涛, 刘巧, 聂建云. 老年三阴性乳腺癌患者的临床困境和系统治疗策略[J]. 中国癌症杂志, 2023, 33(5): 506-516.
[13] 吴晶, 周娟, 苏春霞. 肺癌脂肪酸代谢重编程的研究进展[J]. 中国癌症杂志, 2023, 33(5): 517-526.
[14] 中国临床肿瘤学会免疫治疗专家委员会, 上海市抗癌协会肿瘤生物治疗专业委员会. 基因重组溶瘤腺病毒治疗恶性肿瘤临床应用中国专家共识(2022年版)[J]. 中国癌症杂志, 2023, 33(5): 527-548.
[15] 蒋金玲, 周尘飞, 王超, 赵丽琴, 吴珺玮, 张俊. 2022年度胃癌研究和诊疗新进展[J]. 中国癌症杂志, 2023, 33(4): 303-314.